Europe’s Controlled Medicines Rules Split Into Four Distinct Regulatory Models, Study Finds

Medicines containing controlled substances sit at one of the most delicate intersections in modern healthcare. Opioid analgesics, benzodiazepines, barbiturates, selected antiepileptics and opioid substitution therapies are indispensable for treating acute and chronic pain, delivering anesthesia, easing palliative care and managing certain psychiatric disorders. Yet the same molecules carry serious risks of misuse, dependence and diversion into illicit channels, a danger underlined by the opioid crisis in North America. Europe has so far avoided an equivalent catastrophe, but surveillance data show persistent heterogeneity in opioid prescribing patterns across countries and settings. A new comparative legal study, published in the journal Pharmacia, has now mapped how ten European jurisdictions regulate these medicines and found a patchwork of national systems built on top of a shared international framework, with four clearly distinguishable regulatory models emerging from the analysis.

The research team conducted a doctrinal legal analysis combined with a normative-comparative approach, examining the national legislation of nine EU Member States—Belgium, Poland, Greece, Ireland, France, Germany, Italy, the Netherlands and Portugal—together with the United Kingdom, which was included because of its historically influential role in European pharmaceutical regulation despite its post-Brexit status. The frameworks reflected the law as it stood on 1 February 2026, drawing on primary legal texts retrieved from official national databases such as Légifrance, Gesetze im Internet, Normattiva, ISAP and legislation.gov.uk, alongside guidance from national regulators and reports from the European Union Drugs Agency. Three authors independently extracted data using a standardized form structured around seven criteria: legal classification, prescribing regime, physical storage, accountability systems, digitalization, destruction procedures and institutional oversight.

The jurisdictions were deliberately chosen to represent the full range of regulatory orientations found in European literature and in country assessments by the International Narcotics Control Board, covering Northern, Western, Southern and Eastern Europe. A country was assigned to a regulatory model when it exhibited the defining features of that model for at least five of the seven criteria, with no directly contradictory features among the remainder. Dual assignment was permitted where a jurisdiction displayed balanced features of two models, as occurred with Ireland. The typology had been formulated as an a priori scaffold from comparative pharmaceutical law scholarship and the INCB assessment framework, and the empirical verification stage confirmed rather than redefined it.

Four models emerged. The first, labeled Centralized-Procedural, groups France, Germany, Italy and Greece. It is characterized by detailed procedural regulation, centralized licensing, specialized prescription forms—notably the triplicate Betäubungsmittelrezepte in Germany and the numbered ricette ministeriali a ricalco in Italy—and strong administrative accountability through pharmaceutical oversight. Its strength lies in high traceability and clearly defined responsibilities; its weakness is a substantial administrative burden and limited flexibility. The second model, Digitalized-Integrated, covers Belgium and Poland, both of which have made electronic systems mandatory at national level: Poland introduced compulsory e-prescriptions for all I-N narcotic and II-P psychotropic drugs on 1 November 2023, after which paper prescriptions became invalid, while Belgium’s Narcoreg platform, mandatory since 1 September 2023, requires business-to-business transfers to be declared within 30 days.

The third, Harm-Reduction model, encompasses the Netherlands and Portugal. Both distinguish sharply between strict medical control of therapeutic use and a public-health-oriented social policy toward users. Portugal is the boldest case: Law 30/2000 decriminalizes possession of personal-use amounts of all controlled substances, up to a ten-day supply, shifting the response from criminal prosecution to administrative and health regulation, while medical use remains strictly controlled under Decreto-Lei 15/93. Evidence reviewed in the study indicates that Portuguese decriminalization, combined with investment in prevention and treatment, did not increase problematic drug use and was associated with improvements in public health indicators, although the model’s sustainability remains debated as patterns of substance use diversify. The Netherlands pairs its two-list Opiumwet system with digital registers in pharmacies and permits for hospital pharmacies issued by the Ministry of Health.

The fourth model, Institutional Accountability, is anchored in the United Kingdom and, jointly, Ireland. Its distinctive feature is the Controlled Drugs Accountable Officer, a designated individual required in every UK organization handling controlled medicines, responsible for standard operating procedures, internal audits and reporting to NHS England and the Care Quality Commission. No equivalent mandatory position exists elsewhere in Europe. Ireland shares the procedural features of the centralized model—bound Controlled Drugs Registers, safe-custody storage rules and supervised destruction—but also provides a designated internal responsible officer analogous to the CDAO, earning it dual placement in Models 1 and 4.

The quantitative contrasts the study documents are striking. Document retention requirements range from two to ten years, with France imposing the longest period: ten years for the narcotics register and destruction records, and three years for prescription copies. Portugal and Poland require five-year retention. Digitalization, operationalized as mandatory electronic use for prescription issuance, dispensing records or business-to-business reporting, was rated high in the Netherlands, Poland and Belgium; intermediate in Greece, Italy and the United Kingdom, where the Electronic Prescription Service covers some Schedule 3 to 5 drugs but Schedule 2 medicines still demand paper FP10PCD forms; and low in France, Germany, Portugal and Ireland, all of which still rely predominantly on paper-based tracking. Germany’s famous yellow triplicate forms, one copy each for prescriber, pharmacy and audit, remain entirely paper-based.

Even emergency provision splits the continent. Ireland permits pharmacists to make emergency supplies of CD2, CD3 and CD4 substances—up to five days of treatment or the minimum pack size—when they judge the supply safe, appropriate and necessary. The United Kingdom takes nearly the opposite position: emergency supply of Schedule 2 and most Schedule 3 drugs is effectively prohibited, with phenobarbital for epilepsy the sole exception. Destruction procedures diverge just as widely, from Belgium’s FAMHP-supervised sealing and three-copy destruction statements, through Poland’s documented transfer to licensed companies and Greece’s annual witnessed destruction events, to the pharmacist-led denaturing performed in French hospitals in the presence of a second pharmacist.

The fragmentation has tangible clinical consequences. The EU’s cross-border electronic prescription infrastructure, eHDSI or MyHealth@EU, currently excludes controlled substances altogether, so regulatory divergence directly disrupts continuity of care for patients with legitimate therapeutic needs who travel within the Union—a growing problem as patient and professional mobility increases. The study’s authors argue that harmonization should not mean uniformity, which they consider both unrealistic and undesirable, but rather the definition of minimum common standards for traceability, destruction documentation and digitalization thresholds, while preserving room for national adaptation. They also call for explicit recognition of hospital pharmacists, whom they describe as the critical legal-clinical interface between regulatory frameworks and daily practice.

From a hospital pharmacy perspective, the findings carry direct operational weight. In the low-digitalization countries, pharmacists shoulder manual paper-based verification, register maintenance and destruction documentation, tasks that consume time and raise the risk of transcription errors and accountability gaps; the Belgian and Polish digital models offer a route to reducing that burden while strengthening traceability. Scoping review evidence cited in the study confirms that inadequate safeguards in hospital controlled substance management are associated with drug diversion, with pharmacy playing a central role in both prevention and detection. The authors acknowledge limitations: the analysis examines codified law rather than implementation or clinical outcomes, uses purposive rather than statistically representative sampling, and involves interpretive judgment in borderline model assignments. Future research, they suggest, could evaluate the real-world effectiveness of each model, explore healthcare professionals’ experiences, analyze incident frequency across systems and assess whether artificial intelligence and blockchain technologies could further enhance traceability and security in this most tightly guarded corner of pharmaceutical practice.

Subject of Research: Comparative national regulation of medicinal products containing controlled substances in nine EU Member States and the United Kingdom

Article Title: Comparative analysis of national regulatory frameworks for medicinal products containing controlled substances in nine selected EU Member States and the United Kingdom

Article References: Stoyanova, D. D., Todorova, A. H., Pesheva, M. T., & Grigorov, E. E. (2026). Comparative analysis of national regulatory frameworks for medicinal products containing controlled substances in nine selected EU Member States and the United Kingdom. Pharmacia, 73, Article e197283. https://doi.org/10.3897/pharmacia.73.e197283

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e197283

Keywords: controlled substances, pharmaceutical regulation, opioids, European Union, hospital pharmacy, digitalization, e-prescription, harm reduction, drug policy, regulatory harmonization, United Kingdom, misuse of drugs